Citation APA
Leleu, X., Fouquet, G., Richez, V., Guidez, S., Duhamel, A., Machuron, F., Karlin, L., Kolb, B., Tiab, M., Araujo, C., Meuleman, N., Malfuson, J. V., Bourquard, P., Lenain, P., Roussel, M., Jaccard, A., Pétillon, M.-O., Belhadj-Merzoug, K., Lepeu, G., Chrétien, M.-L., Fontan, J., Rodon, P., Schmitt, A., Offner, F., Voillat, L., Cereja, S., Kuhnowski, F., Rigaudeau, S., Decaux, O., Humbrecht-Kraut, C., Frayfer, J., Fitoussi, O., Roos-Weil, D., Eisenmann, J. C., Dorvaux, V., Voog, E. G., Attal, M., Moreau, P., Avet-Loiseau, H., Hulin, C., & Facon, T. (2019). Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial. Clinical cancer research, 25(14), 4224-4230. doi:10.1158/1078-0432.CCR-18-3642
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/302977